Search Within

Zhan Yao

Formats
  1. Journal Article (23)
  2. Meeting Abstract (14)
  3. Research Letter (1)
Groups
  1. Sloan Kettering Institute Postdocs (38)
  2. Department of Medicine (36)
  3. Solid Tumor Oncology Division (36)
  4. GSK Faculty (35)
  5. Breast Medicine Service (34)
  6. Molecular Pharmacology and Chemistry Program Faculty (34)

More Groups

People
  1. Neal Rosen (34)
  2. Elisa De Stanchina (12)
  3. Rona Yaeger (12)
  4. Barry Taylor (11)
  5. David Solit (11)
  6. Omar Abdel-Wahab (10)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (5)
  4. 2019 (7)
  5. 2018 (5)
  6. 2017 (5)

More Years

Publications
  1. Cancer Research (11)
  2. Cancer Discovery (5)
  3. Nature (3)
  4. European Journal of Cancer (2)
  5. Neuro-Oncology (2)
  6. Blood (1)

More Publications

Publishers
  1. American Association for Cancer Research (19)
  2. Nature Publishing Group (5)
  3. American Society of Clinical Oncology (2)
  4. Cell Press (2)
  5. Elsevier Inc. (2)
  6. Oxford University Press (2)

More Publishers

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
    Journal Article

    Su, W.; Mukherjee, R.; Yaeger, R.; Son, J.; Xu, J.; Na, N.; Timaul, N. M.; Hechtman, J.; Paroder, V.; Lin, M.; more...
    Molecular Cell (2022)

    Fulltext@MSK | Save
  • Mutant-selective degradation by BRAF-targeting PROTACs
    Journal Article

    Alabi, S.; Jaime-Figueroa, S.; Yao, Z.; Gao, Y.; Hines, J.; Samarasinghe, K. T. G.; Vogt, L.; Rosen, N.; Crews, C. M.
    Nature Communications (2021)

    Fulltext@MSK | Save
  • RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
    Meeting Abstract

    Yuan, X.; Zhang, X.; Du, R.; Cheung, S. H.; Wei, M.; Zhou, C.; Wang, L.; Shearer, T.; Edris, B.; Smith, M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors
    Journal Article

    Wang, J.; Pollard, K.; Allen, A. N.; Tomar, T.; Pijnenburg, D.; Yao, Z.; Rodriguez, F. J.; Pratilas, C. A.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Combined SHP2 and MEK inhibition is effective in models of NF1-deficient malignant peripheral nerve sheath tumors
    Meeting Abstract

    Wang, J.; Pollard, K.; Allen, A.; Tomar, T.; Pijnenburg, D.; Yao, Z.; Rodriguez, F.; Pratilas, C.
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Leveraging systematic functional analysis to benchmark an in silico framework distinguishes driver from passenger MEK mutants in cancer
    Journal Article

    Hanrahan, A. J.; Sylvester, B. E.; Chang, M. T.; Elzein, A.; Gao, J.; Han, W.; Liu, Y.; Xu, D.; Gao, S. P.; Gorelick, A. N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K-RAS mutant tumors
    Journal Article

    Yuan, X.; Tang, Z.; Du, R.; Yao, Z.; Cheung, S. H.; Zhang, X.; Wei, J.; Zhao, Y.; Du, Y.; Liu, Y.; more...
    Molecular Oncology (2020)

    Fulltext@MSK | Save
  • eIF4A regulates ERK activation by controlling the translation of DUSP6
    Meeting Abstract

    Xu, J.; Wendel, H. G.; Pelletier, J.; Yao, Z.; Rosen, N.
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer
    Journal Article

    Yaeger, R.; Kotani, D.; Mondaca, S.; Parikh, A. R.; Bando, H.; Van Seventer, E. E.; Taniguchi, H.; Zhao, H.; Thant, C. N.; de Stanchina, E.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • ARAF activates RAS by antagonizing its interaction with NF1
    Meeting Abstract

    Su, W.; Yaeger, R.; Na, N.; Hechtman, J.; Paroder, V.; Misale, S.; Han, S. W.; Abdel-Wahab, O. I.; McCormick, F.; Rosen, N.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save